Get the Stockscreener App
54.20
0.11%
-0.06
Akero Therapeutics Inc stock is traded at $54.20, with a volume of 1.14M.
It is down -0.11% in the last 24 hours and up +14.15% over the past month.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
See More
Previous Close:
$54.26
Open:
$54.25
24h Volume:
1.14M
Relative Volume:
0.56
Market Cap:
$4.34B
Revenue:
-
Net Income/Loss:
$-269.44M
P/E Ratio:
-14.45
EPS:
-3.75
Net Cash Flow:
$-262.63M
1W Performance:
+0.80%
1M Performance:
+14.15%
6M Performance:
+18.83%
1Y Performance:
+75.80%
1-Day Range:
$54.07
$54.30
1-Week Range:
$53.69
$54.31
52-Week Range:
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Name
Akero Therapeutics Inc
Sector
Industry
Phone
650-487-6488
Address
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Compare AKRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
54.20 | 4.35B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Aug-04-25 | Initiated | TD Cowen | Buy |
| Jan-30-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-27-25 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-24 | Initiated | Citigroup | Buy |
| Apr-22-24 | Resumed | BofA Securities | Neutral |
| Sep-19-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-23 | Initiated | UBS | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-14-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Initiated | Guggenheim | Buy |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Jul-20-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-02-20 | Initiated | H.C. Wainwright | Buy |
| Feb-10-20 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Evercore ISI | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
| Jul-15-19 | Initiated | Jefferies | Buy |
| Jul-15-19 | Initiated | ROTH Capital | Buy |
View All
Akero Therapeutics Inc Stock (AKRO) Latest News
Will Akero Therapeutics Inc. (0K4) stock rise with strong economy2025 Volatility Report & Real-Time Chart Pattern Alerts - newser.com
Heatmap analysis for Akero Therapeutics Inc. and competitorsIPO Watch & Fast Moving Market Watchlists - newser.com
Is Akero Therapeutics Inc. stock a buy before product launchesWeekly Trade Review & Weekly Watchlist for Hot Stocks - newser.com
Can Akero Therapeutics Inc. (0K4) stock beat analyst consensusEarnings Overview Summary & Consistent Growth Stock Picks - newser.com
Will Akero Therapeutics Inc. stock gain from lower inflationTrade Risk Assessment & Precise Entry and Exit Recommendations - newser.com
Why Akero Therapeutics Stock Trounced the Market on Thursday - AOL.com
Chart based analysis of Akero Therapeutics Inc. trendsWeekly Market Outlook & Entry Point Confirmation Signals - newser.com
Is Akero Therapeutics Inc. stock a top pick in earnings seasonPortfolio Risk Summary & Technical Entry and Exit Alerts - newser.com
How high can Akero Therapeutics Inc. stock go2025 AllTime Highs & Low Drawdown Investment Ideas - newser.com
Jennison Associates LLC Grows Stock Position in Akero Therapeutics, Inc. $AKRO - MarketBeat
Will Akero Therapeutics Inc. stock reach Wall Street targetsAnalyst Downgrade & High Conviction Buy Zone Alerts - newser.com
Y Intercept Hong Kong Ltd Takes Position in Akero Therapeutics, Inc. $AKRO - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Update - MarketBeat
Can Akero Therapeutics Inc. (0K4) stock deliver strong annual returnsJuly 2025 WrapUp & Fast Gain Swing Alerts - newser.com
Will Akero Therapeutics Inc. outperform the market2025 Support & Resistance & Fast Entry Momentum Alerts - newser.com
Fatty liver disease companies' multibillion-dollar deals mean fatter walletsSan Francisco Business Times - The Business Journals
Can volume confirm reversal in Akero Therapeutics Inc.2025 Fundamental Recap & Daily Stock Momentum Reports - newser.com
Is Akero Therapeutics Inc. trending in predictive chart modelsJuly 2025 Levels & Weekly High Return Opportunities - newser.com
Emerald Mutual Fund Advisers Trust Has $7.27 Million Stock Position in Akero Therapeutics, Inc. $AKRO - MarketBeat
Is Akero Therapeutics Inc. (0K4) stock included in top ETFsJuly 2025 Trends & Stepwise Trade Signal Guides - newser.com
Can Akero Therapeutics Inc. (0K4) stock surprise with quarterly resultsChart Signals & Entry Point Confirmation Alerts - newser.com
Why Akero Therapeutics Inc. stock is recommended by analystsTrade Analysis Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Altimmune: Competitor Buyouts Plus Regulatory And Clinical Progress (NASDAQ:ALT) - Seeking Alpha
Akero Stock Hits Over 18-Month High On MASH Trial Data: Citi Lauds ‘Best-Case Scenario,’ Retail Exuberant - MSN
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO) - Lelezard
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Using RSI to spot recovery in Akero Therapeutics Inc.July 2025 PreEarnings & Capital Efficient Trade Techniques - newser.com
Akero Therapeutics Inc Stock (AKRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):